Clinical Trial Information
A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination With Tremelimumab ± Lenvatinib Given Concurrently With TACE Compared to TACE Alone in Patients With Locoregional Hepatocellular Carcinoma- Category: Liver
- Status: Active
- Starts: Oct 12, 2023
- Stage: III
- Trial Number: D910VC00001
Principal Investigator: Prajwol Pathak, M.D.
Research Nurse: Wendy Blount, RN, MSN
Description of Trial:
This is a Phase III, parallel, randomized, open-label, sponsor-blinded, 3-arm, multicenter, international study assessing the efficacy and safety of durvalumab + tremelimumab + TACE with or without lenvatinib compared with TACE alone in participants with locoregional HCC not amenable to curative therapy (eg, surgical resection, transplantation, or ablation).
For more information, click here.